Advertisement

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Opening Session Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Jul
09
Today In Oncology
Oral Cancer Novel Diagnostic Test Demonstrates High Accuracy
Novel Gene Fusion Detector for Pediatric B-ALL Shows High Sensitivity
AML All-Oral Regimen Safe and Eases Treatment Administration Burden
Investigators Identify Resistance Mechanism to Tagraxofusp Among Patients With BPDCN
All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo